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Aims: Transesophageal echocardiography (TEE) is the gold standard for the detection of thrombi in patients with
atrial fibrillation (AF) before undergoing early electrical cardioversion (CV). However, TEE generates inconclusive
results in a considerable number of patients. This study investigated the influence of contrast enhancement on
interpretability of TEE for the detection of left atrial (LA) thrombi compared to conventional TEE and assessed,
whether there are differences in the rate of thromboembolic events after electrical cardioversion.
Methods: Of 180 patients with AF (51 females, 65.2±13 years) who were referred to CV, 90 were examined with
native imaging and contrast enhancement within the same examination (group 1), and 90 were examined with
native TEE alone and served as control (group 2). Cineloops of the multiplane examination of the LA and LA
appendage (LAA) were stored digitally before and, in group 1, after intravenous bolus application of a
transpulmonary contrast agent. Images of group 1 were assessed offline and the diagnosis of LA thrombi was
made semi-quantitatively: 1= thrombus present; 2=inconclusive result; 3=no thrombus. The presence of
spontaneous echocontrast (SEC) was registered and flow velocity in the LA appendage (LAA-flow) was measured.
All patients in whom CV was performed were followed up for 1 year or until relapse of AF. CV related adverse
events were defined as any thromboembolic event within 1 week after CV.
Results: No serious adverse events occurred during TEE and contrast enhanced imaging. In group 1 atrial thrombi
were diagnosed in 14 (15.6%) during native and in 10 (11.1%) patients during contrast enhanced imaging (p<0.001).
Of the 10 patients with thrombi in the contrast TEE group, 7 revealed a decreased LAA-flow (≤0,3m/s) and 8
showed moderate or marked SEC. Uncertain results were significantly more common during native imaging than
with contrast enhanced TEE (16 vs. 5 patients, p<0.01). Thrombi could definitely be excluded in 60 (66.7%) during
conventional and in 75 patients (83.3%) during contrast enhanced TEE (p<0.01). CV was performed subsequently
after exclusion of thrombi and at the discretion of the investigator. In group 1, 74 patients (82.2%) were
cardioverted and no patient suffered a CV related complication (p=0.084). In group 2, 76 patients (84.4%)
underwent CV, of whom 3 suffered a thromboembolic complication after CV (2 strokes, 1 peripheral embolism).
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Conclusion: In patients with AF planned for CV contrast enhancement renders TEE images more interpretable,
facilitates the exclusion of atrial thrombi and may reduce the rate of embolic adverse events.
Keywords: Atrial fibrillation, Atrial thrombus, Contrast echocardiography, Transesophageal echocardiography,
Cardioversion, Thromboembolic eventsBackground
Transpulmonary contrast agents improve endocardial
border delineation of left sided cardiac chambers. Is has
been predominantly used for the depiction of the left
ventricle and identification of wall motion abnormalities
and cardiac masses [1-3]. Despite preliminary promising
data for the use of a transpulmonary ultrasound contrast
agent for the visualization of the left atrium (LA) and left
atrial appendage (LAA) during transesophageal echocardi-
ography (TEE) [4-6], its application for the detection or
exclusion of thrombi in patients with atrial fibrillation
prior to cardioversion has not been implemented into
clinical routine. Several reasons may account for this cir-
cumstance. First, clinicians may belief that native TEE
alone or with consideration of predictive markers of
thrombus formation such as pulsed wave Doppler meas-
urement of the blood flow in the LAA (LAA-flow) and as-
sessment of spontaneous echo contrast (SEC) allows for
the save exclusion of atrial thrombi in all patients. Fur-
thermore, the prevalence of a LAA thrombus is low with
only 5-13% [7,8] in patients with atrial fibrillation and
without therapeutic anticoagulation and the risk of an
embolic event after cardioversion is even lower [9,10].
Moreover, the application of an ultrasound contrast agent
increases the examination time and expenses.
However, even with the use of TEE and surrogate
parameters such as SEC and LAA-flow, there is an em-
bolic rate of about 1% after electrical cardioversion for
atrial fibrillation [9]. In addition, thrombi in the LAA
can be present in the absence of SEC [8].
The aim of this study was to determine whether the
use of contrast enhancement during TEE can improve
the ability to identify or exclude LA and LAA thrombi
compared to conventional native imaging in patients
with atrial fibrillation (AF) before cardioversion. Further-
more, we assessed if there was a difference in the rate of
thromboembolic events after cardioversion compared to
a control group.Methods
Patients
The study protocol was designed to conform to the prin-
ciples outlined in the Declaration of Helsinki. Informed
consent was obtained from all patients prior to inclusion
into the study. Our study was an observational single-
centre study designed on an intention-to-cardiovertbasis. 180 consecutive patients with AF and indication
for CV were randomized by the investigators within the
same study period to either receive a TEE with add-
itional contrast enhancement (group 1) or a conven-
tional native TEE (group 2). The baseline characteristics
are shown in Table 1. Exclusion criteria were the pres-
ence of other more severe clinical conditions such as
instable angina, acute coronary syndrome, lack of patient
consent as well as contraindications to CV, to TEE or to
application of transpulmonary ultrasound contrast
agents. Anticoagulation therapy was not required before
TEE but was started after TEE if patients were deemed
eligible for CV. In the remaining patients, i.e. those not
suitable for CV, anticoagulation was started according to
CHADS2-Score and as recommended in the ESC-
guidelines for the management of patients with AF [11].
Echocardiography
Cineloops of the multiplane examination of the LA and
LAA were digitally recorded (Philips IE33, GE Vivid VII)
throughout each imaging method. Blood flow velocities
of the atrial appendage were measured by pulsed wave
doppler echocardiography. For the purpose of the present
investigation, in group 1 echocardiographic images were
acquired before and after bolus application of 1ml contrast
agent (SonoVue™ Bracco Diagnostics Inc., Princeton, NJ,
USA) into an antecubital vein followed by a bolus of 5-
10ml saline according to our standardized study protocol.
To avoid shadowing or swirling artefacts, the timing of
image acquisition, mechanical index and the setting of the
focus zone were individually optimised. Figure 1 depicts
examples of native and contrast enhanced TEE.
Data reading
For the evaluation of interpretability of native versus con-
trast enhanced TEE, two experienced observers reviewed
the digital images during an offline analysis without know-
ledge of the current patient and the result of the respective
other imaging method in group 1. In case of disagreement
consensus was sought and achieved in every instance in a
second joint session of both observers. The following clas-
sification was applied: 1= definite thrombus in at least one
imaging plane, 2= inconclusive result in at least one im-
aging plane and 3= no thrombus in all imaging planes.
The images of the patients in group 2 (control group)
were only divided into the clinically relevant categories
Table 1 Patient characteristics (* pro-BNP was not







Age 65.9±12 64.5±13 0.474
female, % 32.2 24.4 0.247
BMI, kg/m2 27.9±5.0 26.2±4.1 0.111
history of TIA/Stroke, % 4.8 2.7 0.522
COPD ≥ °II, % 4.8 8.2 0.433
diabetes mellitus, % 21.3 13.7 0.244
hypertension, % 58.7 60.3 0.855
CAD, % 27.7 28 0.968
previous.MI, % 4.8 6.8 0.606
hyperlipoproteinemia, % 20.6 20.3 0.958
heart rate 1/min 91.7±26 92.8±24 0.803
antiocoagulation ≥1 day
(prior to TEE, %)
51 48 0.764
antiocoagulation ≥3w
(prior to TEE, %)
13 11 0.544
hemoglobinn (g/dl) 14.2±1.7 14.3±1.7 0.834
pro-BNP (pg/ml) * 1817±1700* * *
creatinine (mg/dl) 1.1±0.49 1.1±0.28 0.728
potassium (mmol/l) 4.2±0.43 4.2±0.43 0.928
C-reactive protein (mg/dl) 1.1±2.1 1.5±2.9 0.377
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thrombus suspected, CV possible, respectively. Addition-
ally, the prevalence and severity of atrial spontaneous echo
contrast was graded semiquantitatively (1=none, 2=mild
to moderate and 3=marked).
Cardioversion and follow-up
Electrical CV was done if no intracavitary thrombus was
found or suspected, and postponed in the presence of aFigure 1 Example of native (A) and contrast enhanced (B) TEE in a pa
sludge-like material in the tip of the LAA during native imaging and
transpulmonary contrast agent).thrombus. In less conclusive results, the decision for or
against CV was taken at the examiner’s discretion. ECG
was monitored during the procedure and for 2 hours
after the CV. All patients received anticoagulation treat-
ment starting before and for a minimum of 4 weeks after
CV. CV was considered successful if the patient was in
sinus rhythm after the procedure for at least 5 beats. In
patients with confirmed or suspected thrombus, CV was
postponed until anticoagulation had reached an INR-
value of ≥2.0 for at least 3 weeks and a subsequent TEE
demonstrated disappearance of the thrombus.
All patients were followed up for at least 12 months
after CV or until occurrence of a thromboembolic event.
The first follow-up was conducted 4 weeks after CV
with special anamnestic emphasis on symptoms related
to thromboembolic events and recurrence of arrhythmia
and clinical cardiac and neurologic examination. In case
of suspected thromboembolic event, additional examina-
tions like magnetic resonance tomography were per-
formed. CV related adverse events were defined as any
thromboembolic event within 1 week after CV.
Statistical analysis
The statistical analyses were performed using SPSS stat-
istical software (version 19.0).
The results are given as mean ± standard deviation or
percentages where appropriate. Two-by-two tables were
constructed to analyse associations between the groups.
Significance was tested using Chi-square test for cat-
egorical and student t-test for parametric variables. A
correction for possible cofounders between the two
groups was planned using a propensity adjustment, but
no parameter of the baseline characteristics differed sig-
nificantly (see Table 1). The level of significance for test-
ing all null hypotheses was a two-tailed p-value of 0.05.
Since a calculation of the sample size to demonstrate atient with atrial fibrillation (arrows: left atrial appendage with
homogenous contrast distribution after application of the
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enhanced TEE compared to native TEE (80% power,
confidence level 95%) estimated a required group of
2500 patients, this was not the primary objective of our
study.
Results
No adverse events related to the application of the con-
trast agent occurred. No significant differences between
both groups in age, comorbidities or baseline laboratory
values were found (Table 1). In about half of the patients
(group 1: 51%, group 2: 48%) oral anticoagulation or
heparin was started at least 1 day prior to TEE, only a
minority (group 1: 13%, group 2: 11%) were anticoagulated
for at least 3 weeks (Table 1). In all patients anticoagula-
tion was started/continued according to CHADS2-Score
and as recommended in the ESC-guidelines for the man-
agement of patients with AF [11].
In group 1, the definite existence of a thrombus
(classification 1) was assumed in 14 (15.6%) patients
during initial examination without contrast enhance-
ment and in 10 (11.1%) patients after the contrast
agent was applied (Figure 2). Of the 14 patients with
thrombus detection at native imaging, 8 were con-
firmed by contrast enhanced TEE, 2 remained unclear
and in 4 patients a thrombus could be safely excluded
and CV performed without subsequent complications.
Contrast enhancement allowed for the additional iden-
tification of 2 patients with thrombi, in whom native
imaging yielded non distinctive findings.
In group 1 inconclusive diagnostic findings, defined as lack
of definite identification or exclusion of a thrombus in the
multiplane examination of the LA and LAA (classification 2),
resulted in 16 patients (17,8%) during native imaging
and in 5 (5.6%) patients after application of the con-
trast agent (p<0.001; Figure 2). In 11 of the 16 patientsFigure 2 TEE diagnosis before and after application of contrast agentwith previously uncertain results contrast application
allowed for exclusion of thrombi, 3 exams remained un-
clear and in 2 patients a thrombus was newly diagnosed.
Definite exclusion of atrial thrombi using the above
mentioned criteria was feasible in 60 (66.7%) during
conventional and in 75 patients (83.3%) during contrast
enhanced TEE (p<0.001).
The patients in group 2 served as control for subse-
quent events. Possible results of the TEE were categor-
ized in 1=Thrombus suspected, CV postponed/refused
and 2=no thrombus suspected, CV possible, respectively.
10 patients (11.1%) in the control group were supposed
to have an atrial thrombus, in the remaining 80 patients
(88.9%) no thrombus was suspected of whom 76 (84.4%)
were cardioverted subsequently. The success rate of CV
was 94.6% in group 1 (70/74 successful CV) and 92.1%
in the control group (71/76 successful CV, p=0.73).
We found that in both study groups the average blood
flow velocity in the LAA was significantly lower in patients
in whom a thrombus could be detected than in those with-
out a thrombus or inconclusive results (group 1: 0.32m/s
vs. 0.47m/s, p=0.05; group 2: 0.29m/s vs. 0.48m/s, p=0.03).
Accordingly, the presence of moderate or marked spon-
taneous echo contrast in the LAA was higher in patients
with atrial thrombi (group 1: 8 of 10 patients [12] vs. 45 of
80 patients [13], p=0.043; control group: 10 of 10 patients
[14] vs. 55 of 80 patients [3], p<0.001).
Of the 10 patients with a definite thrombus after con-
trast enhanced TEE (group 1), 7 showed a concurrent
severe reduction in left atrial appendage blood flow vel-
ocity (≤0.3m/s) and in 2 patients no or mild SEC was
found.
Cardioversion was carried out at the discretion of the
investigator and performed in 74 (82.2%) patients in
group 1 and 76 (84.4%) patients in the control group
(p=0.514, Table 2). In the control group 3 patients (3.9%)(group 1).
Table 2 Echocardiographic results and follow up (*1
patient with an event 10 days after CV was excluded due








thrombus detected (%) 10 (11.1) 10 (11.1)
LAA-flow (m/s) 0.32 ±0.2 0.29 ±0.2 0.75
LAA-flow ≤ 0.3m/s (%) 7 (70) 8 (80) 0.606
SEC (no/minor-moderate/
marked)
2 / 6 / 2 0 / 4 / 6 0.111
LA diameter (mm) 47.6±7.2 50.1±6.1 0.429
thrombus excluded /
unclear
80 (88.9) 80 (88.9)
LAA-flow (m/s) 0.47 ±0.2 0.48 ±0.2 0.711
SEC (no/minor-moderate/
marked)
35 / 38 / 7 25 / 48 / 7 0.243
LA diameter (mm) 46.5±6.3 46.6±7.3 0.895
CV performed (%) 74 (82.2) 76 (84.4) 0.514
CV related events (%) 0 (0)* 3 (3.9) 0.084
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those, 1 patient had an ischemic stroke immediately dur-
ing cardioversion, 1 patient had an ischemic stroke 2
days after cardioversion and 1 had a peripheral embol-
ism of the A. poplitea 2 days after CV.
No CV related adverse event occurred in the contrast
enhanced TEE group (p=0.084, Chi-square). However,
one patient in the contrast-enhanced TEE-group suf-
fered a peripheral thromboembolic event 10 days after
successful CV, but had discontinued anticoagulation
against medical advice immediately after CV. This patients
TEE had shown marked SEC and depressed LAA blood
flow and strict anticoagulation has been advised. Due to
study protocol violation (cessation of anticoagulation) and
time after CV (embolism beyond predefined time period
of CV related events of 1 week), this episode did not
account a CV related event.
Discussion
TEE is the method of choice to exclude thrombus for-
mation in the LA before CV in patients with AF [15], no
other imaging modality has so far been able to demon-
strate a similar accuracy [16]. Nonetheless, even with the
use of TEE and surrogate parameters such as SEC and
LAA-flow, there is an embolic rate of about 1% after
electrical CV [9] that may be a consequence of subopti-
mal image quality during TEE. Therefore, it is essential
to exclude possible atrial thrombi before the procedure
using the best imaging method.
Our patient group was comparable to that of other AF
studies regarding age, comorbidities and presence ofatrial thrombi [7-9]. In our study, the use of the contrast
agent during TEE was feasible and safe, no adverse
events related to its application occurred throughout the
examination and follow up. This was in good accordance
with other studies using the same contrast agent [3,17].
Contrast enhanced TEE permitted the exclusion of
thrombi in 4 patients, in whom thrombi were suspected
during native imaging. This can be explained by the cap-
ability of the contrast agent to completely opacify the
LAA even in the presence of artefacts during native im-
aging leading to falsely identification of thrombi [4]. In 2
patients (2.2%) the contrast application allowed for the
additional delineation of atrial thrombi and suspension
of the scheduled CV. In these cases, native TEE was not
able to detect the atrial thrombi due to insufficient
image quality and low degree of echogenicity of the
thrombotic material, whereas a persisting contrast-free
area in the tip of the LAA during contrast enhanced im-
aging indicated the presence of a thrombus. In accord-
ance with the results of Recke et al. [4] the number of
not conclusive TEE decreased significantly (5.6% vs.
17.8%) using contrast enhancement and therefore facili-
tated decision making for or against CV.
Some authors suggest that the additional use of surro-
gate parameters such as the presence of SEC and low
LAA-flow allows for the confident identification of
patients with low risk of CV related thromboembolic
events [18]. However, thrombi in the LAA can be
present in the absence of SEC [8]. In our study, 3 of the
10 patients with a definite thrombus after contrast
enhanced TEE showed only mild reduction in left atrial
appendage blood flow velocity (0.3-0.5m/s) and 2 patients
none or only mild SEC. We and other authors therefore
conclude that surrogate parameters cannot replace the
direct visualisation of the LAA [14] since the duration of
AF, the LA size and other factors influence the amount of
SEC and LAA-flow.
CV was carried out at the discretion of the investigator
and performed in 74 (82.2%) patients in group 1 and 76
(84.4%) patients in the control group (p=0.514, Table 2).
A possible explanation for this lack of difference between
the groups might be the fact, although not significant
(p=0.514), that the contrast application can facilitate the
visualisation of the sometimes impressive slow blood flow
in the LAA. This effect has also been shown in previous
studies [6] and may have led to the decision against CV in
some patients in whom atrial function was severely
depressed despite exclusion of a thrombus.
The event rate in our study was 3.9% in the control
group, where native TEE was performed, and 0% in group
1 using contrast enhancement. Previous studies showed
embolic complications of CV in as much as 1% of patients
despite exclusion of thrombi with conventional TEE [9].
This corresponds well to the finding of another study
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where 2 of 213 patients had a thrombus despite a normal
TEE [19]. In our study the slightly higher event rate in
group 2 compared to literature may be a consequence of
selection bias or higher cardiac morbidity including
patients with valve disease and heart failure. The differ-
ence to group 1 (0% event rate) is best explained as a con-
sequence of improved interpretability after contrast
application, but did not, however, reach statistical signifi-
cance (p=0.08). Planned as a single centre study and tak-
ing into account a low rate of CV related events, the
objective of our study was to test feasibility of contrast
enhanced TEE and concomitant improvement of inter-
pretability rather than superiority of contrast enhanced
TEE regarding subsequent thromboembolic events.
It can be hypothesised from the above mentioned
comparison of TEE and intraoperative findings and an-
other study published by Saeed et al. [10] that even in
the presence of an atrial thrombus CV does not neces-
sarily provoke a thromboembolic complication, and that
the estimated risk is therefore somewhat lower. This cir-
cumstance contributes to the explanation of the low
event rate after CV despite the lack of diagnostic accuracy
of conventional TEE. The rare appearance of thrombo-
embolism after CV, however, contrasts to its severity with
persisting disabling sequelae for the patient. Hence, it
appears to be essential to eliminate possible atrial thrombi
before the procedure using the best method possible. In
our opinion, despite the low event rate, the contrast im-
aging related increase in duration of the examination and
the additional expenses, contrast application should be
performed whenever native imaging does not allow for
the safe exclusion of atrial thrombi.
Limitations
The study was conducted on an observational basis without
blinding. Therefore, a selection bias as well for the patients
as for the examiner may be present. Another possible limi-
tation was that there was no anatomical gold standard to
confirm the results of TEE, as could be provided in case of
subsequent cardiac surgery and direct visual validation.
Furthermore, contrast enhanced TEE cannot accurately dif-
ferentiate between new and old/organised thrombi, that
may not contribute to an increased thromboembolic risk.
The estimated rate for cardioembolic events after cardi-
oversion in the literature is about 1%. On the basis of this
low event rate, the estimated sample size to reliably con-
firm the superiority of contrast enhanced TEE for the pre-
vention of embolic events in patients undergoing CV is
far higher than our study group, which was therefore
underpowered to show superiority regarding CV related
events. Consequently, further examinations should be car-
ried out to clarify the precise benefit of contrast enhance-
ment during TEE in a larger patient group.Conclusion
Our study shows that application of an ultrasound con-
trast agent during TEE is feasible and has the potential
of reducing equivocal diagnostic findings for the identifi-
cation of LA thrombi in patients with AF referred to
CV. There was a trend to less thromboembolic compli-
cations after CV if a contrast agent was used for the ex-
clusion of thrombi during TEE.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PJ initiated the study, recruited patients, carried out most of the
echocardiographic studies, contacted patients during follow-up, analysed the
data and drafted the manuscript. MM performed echocardiographic
examinations and contributed to the writing of the manuscript. CS, ME. PS
and GS assisted in the patient recruitment, echocardiographic examinations
and performed electrical cardioversions. RD assisted in the
echocardiographic examinations and the statistical analysis of the data. JR
recruited patients eligible for the study and performed electrical
cardioversions. SK conceived of the interpretation of the data and reviewed
the manuscript carefully. HYS provided the infrastructure necessary for the
realization of the study, conceived of the interpretation of the data and
reviewed the manuscript carefully. All authors read and approved the final
manuscript.
Received: 8 August 2012 Accepted: 20 December 2012
Published: 7 January 2013
References
1. Olszewski R, Timperley J, Szmigielski C, Monaghan M, Nihoyannopoulos P,
Senior R, Becher H: The clinical applications of contrast
echocardiography. Eur J Echocardiogr 2007, 8(3):S13–S23.
2. Bednarz JE, Spencer KT, Weinert L, Sugeng L, Mor-Avi V, Lang RM:
Identification of cardiac masses and abnormal blood flow patterns with
harmonic power Doppler contrast echocardiography. J Am Soc
Echocardiogr 1999, 12(10):871–875.
3. Jung PH, Rieber J, Stork S, Hoyer C, Erhardt I, Nowotny A, Voelker W,
Weidemann F, Ertl G, Klauss V, et al: Effect of contrast application on
interpretability and diagnostic value of dobutamine stress
echocardiography in patients with intermediate coronary lesions:
comparison with myocardial fractional flow reserve. Eur Heart J 2008,
29(20):2536–2543.
4. von der Recke G, Schmidt H, Illien S, Luderitz B, Omran H: Use of
transesophageal contrast echocardiography for excluding left atrial
appendage thrombi in patients with atrial fibrillation before
cardioversion. J Am Soc Echocardiogr 2002, 15(10 Pt 2):1256–1261.
5. Yao SS, Ilercil A, Meisner JS, Strom JA, Shirani J: Improved Doppler
echocardiographic assessment of the left atrial appendage by
peripheral vein injection of sonicated albumin microbubbles. Am
Heart J 1997, 133(4):400–405.
6. Kato H, Nakanishi M, Maekawa N, Ohnishi T, Yamamoto M: Evaluation of
left atrial appendage stasis in patients with atrial fibrillation using
transesophageal echocardiography with an intravenous albumin-
contrast agent. Am J Cardiol 1996, 78(3):365–369.
7. Manning WJ, Silverman DI, Gordon SP, Krumholz HM, Douglas PS:
Cardioversion from atrial fibrillation without prolonged anticoagulation
with use of transesophageal echocardiography to exclude the presence
of atrial thrombi [see comments]. N Engl J Med 1993, 328(11):750–755.
8. Fatkin D, Kelly RP, Feneley MP: Relations between left atrial appendage
blood flow velocity, spontaneous echocardiographic contrast and
thromboembolic risk in vivo. J Am Coll Cardiol 1994, 23(4):961–969.
9. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW,
Davidoff R, Erbel R, Halperin JL, Orsinelli DA, et al: Use of transesophageal
echocardiography to guide cardioversion in patients with atrial
fibrillation. N Engl J Med 2001, 344(19):1411–1420.
10. Saeed M, Rahman A, Afzal A, Agoston I, Jammula P, Birnbaum Y, Ware DL,
Uretsky BF, Schwarz ER, Rosanio S: Role of transesophageal
Jung et al. Cardiovascular Ultrasound 2013, 11:1 Page 7 of 7
http://www.cardiovascularultrasound.com/content/11/1/1echocardiography guided cardioversion in patients with atrial fibrillation,
previous left atrial thrombus and effective anticoagulation. Int J Cardiol
2006, 113(3):401–405.
11. Fuster V, Ryde’n LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA,
Halperin JL, Jean-Yves Le H, Kay GN, Lowe JE, et al: ACC/AHA/ESC 2006
guidelines for the management of patients with atrial fibrillation: full
text. Europace 2006, 8:651–745.
12. Fischer JJ, Samady H, McPherson JA, Sarembock IJ, Powers ER, Gimple LW,
Ragosta M: Comparison between visual assessment and quantitative
angiography versus fractional flow reserve for native coronary
narrowings of moderate severity. Am J Cardiol 2002, 90(3):210–215.
13. Tavakoli R, Weber A, Vogt P, Brunner HP, Pretre R, Turina M: Surgical
management of acute mitral valve regurgitation due to post-infarction
papillary muscle rupture. J Heart Valve Dis 2002, 11(1):20–25. discussion 26.
14. Ayirala S, Kumar S, O'Sullivan DM, Silverman DI: Echocardiographic
predictors of left atrial appendage thrombus formation. J Am Soc
Echocardiogr 2011, 24(5):499–505.
15. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC,
Al-Attar N, Hindricks G, Prendergast B, et al: Guidelines for the
management of atrial fibrillation: the Task Force for the Management of
Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J
2010, 31(19):2369–2429.
16. Dorenkamp M, Sohns C, Vollmann D, Luthje L, Seegers J, Wachter R, Puls M,
Staab W, Lotz J, Zabel M: Detection of left atrial thrombus during routine
diagnostic work-up prior to pulmonary vein isolation for atrial
fibrillation: Role of transesophageal echocardiography and multidetector
computed tomography. Int J Cardiol 2011, S0167-5273(11):00681–00684.
17. Dijkmans PA, Senior R, Becher H, Porter TR, Wei K, Visser CA, Kamp O:
Myocardial contrast echocardiography evolving as a clinically feasible
technique for accurate, rapid, and safe assessment of myocardial
perfusion: the evidence so far. J Am Coll Cardiol 2006, 48(11):2168–2177.
18. Thambidorai SK, Murray RD, Parakh K, Shah TK, Black IW, Jasper SE, Li J,
Apperson-Hansen C, Asher CR, Grimm RA, et al: Utility of
transesophageal echocardiography in identification of thrombogenic
milieu in patients with atrial fibrillation (an ACUTE ancillary study).
Am J Cardiol 2005, 96(7):935–941.
19. Hwang JJ, Chen JJ, Lin SC, Tseng YZ, Kuan P, Lien WP, Lin FY, Chu SH,
Hung CR, How SW: Diagnostic accuracy of transesophageal
echocardiography for detecting left atrial thrombi in patients with
rheumatic heart disease having undergone mitral valve operations.
Am J Cardiol 1993, 72(9):677–681.
doi:10.1186/1476-7120-11-1
Cite this article as: Jung et al.: Contrast enhanced transesophageal
echocardiography in patients with atrial fibrillation referred to electrical
cardioversion improves atrial thrombus detection and may reduce
associated thromboembolic events. Cardiovascular Ultrasound 2013 11:1.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
